Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) FCF Margin (2018 - 2025)

UroGen Pharma (URGN) has disclosed FCF Margin for 8 consecutive years, with 101.33% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, FCF Margin fell 4543.0% year-over-year to 101.33%, compared with a TTM value of 148.22% through Dec 2025, down 4085.0%, and an annual FY2025 reading of 148.22%, down 4085.0% over the prior year.
  • FCF Margin was 101.33% for Q4 2025 at UroGen Pharma, up from 154.13% in the prior quarter.
  • Across five years, FCF Margin topped out at 55.47% in Q4 2023 and bottomed at 369.91% in Q1 2021.
  • Average FCF Margin over 5 years is 140.85%, with a median of 135.62% recorded in 2021.
  • The sharpest move saw FCF Margin surged 636378bps in 2021, then crashed -5597bps in 2025.
  • Year by year, FCF Margin stood at 125.34% in 2021, then increased by 4bps to 120.3% in 2022, then surged by 54bps to 55.47% in 2023, then dropped by -1bps to 55.91% in 2024, then tumbled by -81bps to 101.33% in 2025.
  • Business Quant data shows FCF Margin for URGN at 101.33% in Q4 2025, 154.13% in Q3 2025, and 165.05% in Q2 2025.